Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma

Abstract

Immune response correlates with endometrial cancer molecular subtype but does not carry independent prognostic significance. Profound variation in immune response is seen across and within endometrial cancer molecular subtypes, suggesting that assessment of immune response rather than molecular subtype may better predict response to immunotherapy.<i>See related commentary by Mullen and Mutch, p. 2366</i>.